Sanofi (SNY) EBITDA (2009 - 2026)

Sanofi has disclosed EBITDA across 18 years of filings, most recently posting $1.2 billion for Q2 2026.

• In Q2 2026, EBITDA fell 27.06% year-over-year to $1.2 billion; the TTM figure through Jun 2026 stood at $6.7 billion (down 21.29% YoY), while the FY2025 annual figure was $7.4 billion, down 5.92% from the prior year.
• EBITDA came in at $1.2 billion for Q2 2026 at Sanofi, down from $2.5 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $8.6 billion in Q3 2025 to a low of -$5.6 billion in Q4 2025.
• Average EBITDA over 5 years is $2.6 billion, with a median of $2.4 billion recorded in 2026.
• The largest YoY upside for EBITDA was 122.04% in 2025 against a maximum downside of 1011.95% in 2025.
• Over 5 years, EBITDA stood at $6.7 billion in 2022, then advanced by 12.01% to $7.5 billion in 2023, then plunged by 91.82% to $612.3 million in 2024, then slumped by 1011.95% to -$5.6 billion in 2025, then jumped by 121.79% to $1.2 billion in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $1.2 billion in Q2 2026, $2.5 billion in Q1 2026, and -$5.6 billion in Q4 2025.